Efferalgan (paracetamol) effervescent tablets 500 mg. №16


Manufacturer: France

Symptomatic treatment of diseases accompanied by mild to moderate pain and / or fever.



Efferalgan Composition
active substance: paracetamol;

1 effervescent tablet contains paracetamol 500 mg

Efferalgan excipients: citric acid, sodium carbonate anhydrous, sodium bicarbonate, sorbitol (E 420), sodium saccharin, sodium docusate, povidone, sodium benzoate (E 211).

Efferalgan Dosage form
Effervescent tablets.

Basic physical and chemical properties: white tablets with beveled edges with a notch for dividing, dissolve in water with an effervescent reaction, the presence of chips is permissible.

Pharmacotherapeutic group
Analgesics and antipyretics. ATX code N02B E01.

Paracetamol has analgesic, antipyretic and anti-inflammatory effects.

Paracetamol is rapidly and almost completely absorbed in the gastrointestinal tract. The maximum concentration in blood plasma is reached after 30-60 minutes. The half-life is 1-4 hours. It is evenly distributed in all body fluids. Plasma protein binding is variable. It is excreted mainly by the kidneys in the form of conjugated metabolites.

Symptomatic treatment of diseases accompanied by pain of mild to moderate intensity and / or an increase in body temperature (infectious and inflammatory diseases, headache, toothache, muscle pain, painful menstruation).

Hypersensitivity to paracetamol or other components of the drug.

Severe liver and / or kidney dysfunctions, congenital hyperbilirubinemia, glucose-6-phosphate dehydrogenase deficiency, blood diseases, Gilbert’s syndrome, severe anemia, leukopenia.

Fructose intolerance (since the drug contains sorbitol).


Interaction with other medicinal products and other forms of interaction
The absorption rate of paracetamol may increase due to the simultaneous use with metoclopramide and domperidone and decrease due to the use with cholestyramine. The anticoagulant effect of warfarin and other coumarins may increase with the simultaneous long-term regular daily use of paracetamol with an increased risk of bleeding. Periodic intake has no significant effect.

Barbiturates reduce the antipyretic effect of paracetamol.

Anticonvulsants (including phenytoin, barbiturates, carbamazepine), which stimulate the activity of liver microsomal enzymes, can increase the toxic effect of paracetamol on the liver due to an increase in the conversion of the drug to hepatotoxic metabolites. With the simultaneous use of paracetamol with isoniazid, the risk of developing hepatotoxic syndrome increases. Paracetamol reduces the effectiveness of diuretics.

Do not use simultaneously with alcohol.

Application features
In case of liver or kidney disease, consult a doctor before using the drug. Before using the drug, it is necessary to consult a doctor if the patient is using warfarin or similar drugs that have an anticoagulant effect.

Patients with severe infections, such as sepsis, that are accompanied by a decrease in glutathione levels while taking paracetamol, have an increased risk of metabolic acidosis.

The symptoms of metabolic acidosis are deep, rapid or labored breathing, nausea, vomiting, and loss of appetite. You should immediately consult a doctor if these symptoms appear.

Do not exceed the indicated doses. If symptoms persist, you should see your doctor.

Do not take the drug at the same time as other products containing paracetamol.

When using paracetamol in children at a dose of 60 mg / kg per day, the combination with other antipyretic drugs is justified only in case of ineffectiveness. Use with caution with a body weight of up to 50 kg, with chronic malnutrition (low reserves of glutathione in the liver), dehydration, mild to moderate liver failure.

Treatment should be discontinued if acute viral hepatitis is detected.